Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study.
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Cyclophosphamide
/ adverse effects
Doxorubicin
/ adverse effects
Drug Interactions
Drug Monitoring
Female
Humans
Lymphoma, Large B-Cell, Diffuse
/ diagnosis
Male
Middle Aged
Neoplasm Staging
Prednisone
/ adverse effects
Prognosis
Treatment Outcome
Vincristine
/ adverse effects
Young Adult
Efficacy
obinutuzumab
safety profile
Journal
Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
pubmed:
3
10
2018
medline:
23
6
2020
entrez:
3
10
2018
Statut:
ppublish
Résumé
This study investigated the safety and efficacy of obinutuzumab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (G-CHOP) in patients with advanced diffuse large B-cell lymphoma (DLBCL) and explored the impact of cell-of-origin (COO) on patient outcomes. Patients (N = 100) received obinutuzumab (1000 mg on the days 1, 8, and 15 of cycle 1, and day 1 of cycles 2-8) plus CHOP (cycles 1-6). For patients without grade ≥3 infusion-related reactions (IRRs) to standard-rate obinutuzumab infusion, a shorter duration of infusion (SDI) was evaluated. Overall and complete response rates, as determined according to the Cheson et al. criteria by investigators/independent radiological facility, were 82.0/75.0% and 55.0/58.0%, respectively. SDI of 120 minutes and 90 minutes were well tolerated with no grade ≥3 IRRs. Among all patients, IRRs typically occurred during cycle 1, day 1. G-CHOP is active and has an acceptable safety profile in the first-line treatment of patients with advanced DLBCL. Clinical Trials: NCT01414855DLBCL.
Identifiants
pubmed: 30277102
doi: 10.1080/10428194.2018.1515940
pmc: PMC6445782
mid: NIHMS1514696
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Vincristine
5J49Q6B70F
Doxorubicin
80168379AG
Cyclophosphamide
8N3DW7272P
obinutuzumab
O43472U9X8
Prednisone
VB0R961HZT
Banques de données
ClinicalTrials.gov
['NCT01414855']
Types de publication
Clinical Trial, Phase II
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
894-903Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Références
Blood. 1977 Mar;49(3):325-33
pubmed: 65189
Blood. 2007 Mar 1;109(5):1857-61
pubmed: 17105812
J Clin Oncol. 2011 Jan 10;29(2):200-7
pubmed: 21135273
Clin Cancer Res. 2013 Dec 15;19(24):6686-95
pubmed: 24122791
Leuk Lymphoma. 2014 Oct;55(10):2335-40
pubmed: 24471908
N Engl J Med. 2017 Oct 5;377(14):1331-1344
pubmed: 28976863
Lancet Oncol. 2008 Feb;9(2):105-16
pubmed: 18226581
J Clin Oncol. 2017 Nov 1;35(31):3529-3537
pubmed: 28796588
N Engl J Med. 1993 Sep 30;329(14):987-94
pubmed: 8141877
Lancet. 2013 May 25;381(9880):1817-26
pubmed: 23615461
Adv Ther. 2017 Feb;34(2):324-356
pubmed: 28004361
Nature. 2000 Feb 3;403(6769):503-11
pubmed: 10676951
Blood. 2015 Oct 15;126(16):1869-70
pubmed: 26472733
Blood. 2014 Feb 6;123(6):837-42
pubmed: 24264230
Cancer Treat Rev. 2007 Apr;33(2):161-76
pubmed: 17240533
Leuk Lymphoma. 2005 Nov;46(11):1569-73
pubmed: 16236611
Blood. 2014 Feb 20;123(8):1214-7
pubmed: 24398326
Blood. 2010 Jun 3;115(22):4393-402
pubmed: 20194898
N Engl J Med. 2008 Nov 27;359(22):2313-23
pubmed: 19038878
J Clin Oncol. 2013 Aug 10;31(23):2912-9
pubmed: 23835718
J Clin Oncol. 2006 Jul 1;24(19):3121-7
pubmed: 16754935
J Natl Compr Canc Netw. 2016 Feb;14(2):196-231
pubmed: 26850490
Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9991-6
pubmed: 12900505
N Engl J Med. 2002 Jan 24;346(4):235-42
pubmed: 11807147
J Clin Oncol. 2007 Feb 10;25(5):579-86
pubmed: 17242396
Leukemia. 2008 Oct;22(10):1917-24
pubmed: 18615101
Leukemia. 2015 Jul;29(7):1578-86
pubmed: 25708834
Lancet Oncol. 2006 May;7(5):379-91
pubmed: 16648042
J Clin Oncol. 2015 Jan 20;33(3):251-7
pubmed: 25135992
N Engl J Med. 2014 Mar 20;370(12):1101-10
pubmed: 24401022
Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):106-11
pubmed: 23276889
N Engl J Med. 1993 Apr 8;328(14):1002-6
pubmed: 7680764